General Hepatology

New name ditches "nonalcoholic" and "fatty," clarifies etiology

Lack of rapid testing and payer restrictions are creating barriers, experts say

Plus, two other studies on retatrutide show benefit in type 2 diabetes, fatty liver disease

Early model suggests a way to predict progression-free survival

Pilot trial demonstrates that FMT can boost gut health, prevent serious infections

Investigational drug more likely to resolve severe form of fatty liver disease, improve fibrosis

Difficulty of risk mitigation for potential drug-induced liver injury weighed heavily on members

Agency reviewers signal little support for first potential nonalcoholic steatohepatitis drug

Risk 40% lower with use among those with preexisting liver disease, study found

Roux-en-Y bypass or sleeve gastrectomy resolved NASH without exacerbating liver fibrosis

Years ago, she had a liver transplant. Now she leads Hopkins' pediatric liver transplant program

More research from the National Kidney Foundation Spring Clinical Meeting

Atezolizumab-bevacizumab reduced the risk of recurrence by about 30%

Goal of 30% reduction in serum creatinine in the absence of full response or HRS reversal